A high-performance liquid chromatography assay to monitor the new antiepileptic drug lacosamide in patients with epilepsy

Therapeutic Drug Monitoring

Volumn 32, Issue 4, 2010, Pages 448-452

  Greenaway, Clare ^a   Ratnaraj, Neville ^a   Sander, Josemir W ^a   Patsalos, Philip N ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

high performance liquid chromatography; lacosamide; new antiepileptic drug; therapeutic drug monitoring

Indexed keywords

CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CLOBAZAM; CLONAZEPAM; ETIRACETAM; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; VALPROIC ACID; VIGABATRIN; ACETAMIDE DERIVATIVE; ANTICONVULSIVE AGENT;

ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG STABILITY; EPILEPSY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; BLOOD; DOSE RESPONSE; PROCEDURES; QUALITY CONTROL; REPRODUCIBILITY; STANDARD;

ACETAMIDES; ANTICONVULSANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; EPILEPSY; HUMANS; QUALITY CONTROL; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS;

EID: 77955173059     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181dcc5fb     Document Type: Article

References (15)

1. Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second-and third-generation antiepileptic drugs. Expert Rev Neurotherapeut. 2010;10:119-140.
2. Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia. 2007;48:1308-1317.
3. Cross SA, Curran MP. Lacosamide: in partial onset seizures. Drugs. 2009; 69:449-459.
4. Halasz P, Kalviainen R, Mazurkiewicz-Beldzinska M, et al; on behalf of the SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled study. Epilepsia. 2009;50:443-453.
5. Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009;83:1-43.
6. Doty P, Rudd GD, Stoehr T, et al. Lacosamide. Neurotherapeutics. 2007;4: 145-148.
7. Beyreuther BK, Freitag J, Heers C, et al. Lacosamide: a review of preclinical properties. CNS Drug Rev. 2007;13:21-42.
8. Ben-Menachem E. Lacosamide: an investigational drug for adjunctive treatment of partial-onset seizures. Drugs Today. 2008;44:35-40.
9. British National Formulary, 58th ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2009.
10. Halford JJ, Lapointe M. Clinical perspectives on lacosamide. Epilpesy Curr. 2009;1:1-9.
11. Luszczki JL. Third generation antiepileptic drugs: mechanism of action, pharmacokinetics and interactions. Pharmacol Rep. 2009;61:197-216.
12. Biton V, Rosendeld WE, Whitrsides J, et al. Intravenous lacosamide in patients with partial-onset seizures. Epilepsia. 2008;48:4118-4424.
13. Kellinghaus C, Berning S, Besselmann M. Intravenous lacosamide as successful treatment for nonconvulsive status epilepticus after failure of first-line therapy. Epilepsy Behav. 2009;14:429-431.
14. Patsalos PN, Berry DJ, Bourgeois BFD, et al. Antiepileptic drugs\best practice guidelines for therapeutic drug monitoring: a position paper by the Subcommission on Therapeutic Drug Monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49:239-1276.
15. Food and Drug Administration. Guidance for Industry: Bioanalytical Method Validation. Rockville MD: US Department for Health and Human Services; 2001. Available at: www.fda.gov/cder/guidance. Accessed October 26, 2009.